Submitted by reuters8361 in business
Novo Nordisk <a href="https://www.reuters.com/markets/companies/NOVOb.CO" target="_blank">(NOVOb.CO)</a> said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim …